期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

C-erbB-2、nm23、p53基因与乳腺癌预后 被引量：1

C-erbB-2,p53 and nm23 gene and Prognosis of Breast Cancer
下载PDF
导出
摘要 本文综述了乳腺癌目前研究较为成熟和有肯定作用的生物学预后因子癌基因C-erbB-2、抑癌基因p53和肿瘤转移抑制基因nm23。它们均与乳腺癌的发生、发展、转移和复发密切相关,是乳腺癌的重要分子标志物和治疗靶。通过对生物学预后因子的研究,特别是多项生物学预后指标的联合检测和应用,并结合临床,从而更为有效、准确地估计乳腺癌患者的预后,并有助于指导乳腺癌的个体化治疗。 In this review, we summarized some prognostic hio-factors, oncogene C-erbB-2, anti-oncogene p53 and anti-metastasis gone nm23, which have been maturely studied and made sure of positive effect. All these factors were closely correlated with the occurrence, progression, metastasis and recurrence of breast cancer, and is an important molecular marker and therapeutic target of breast cancer. Through the study of such prognostic bio-factors, especially the study of combined detection and application of several bio-factors with clinic,we will more effectively and accurately evaluate the prognosis of patients with breast cancer,which is helpful to direct individualized treatment for cancer patients.
作者 丁锦辉 于冰
机构地区 新疆医科大学第二附属医院肿瘤外科
出处 《医学综述》 2006年第11期671-673,共3页 Medical Recapitulate
关键词 乳腺癌 基因 预后 Breast cancer Gene Prognosis
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[ J]. Science, 1987,235 (4785) : 177-182.
  • 2Slamon DJ, Godolphin W, Joneo LA, et al. Studies of the HER-2/neu proto- oncogene in human breast and ovarian cancer[J]. Science,1989,244(4905):707-712.
  • 3Linderholm B, Andersson J, Lindh B, et al. Overexpression of C-erbB-2 is related to a higher expression of vascular endothelial growth factor(VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic trcatmcnt [ J ]. Eur J Cancer, 2004,40( 1 ) : 33-42.
  • 4杨金巧,陈琳,幸天勇.乳腺癌中C-erbB2癌基因与雌、孕激素受体和PS2的关系及其预后意义[J].四川大学学报（医学版）,2004,35(3):334-336. 被引量：36
  • 5Hayes DF, Thor AD. C-erbB-2 in breast cancer: development of a clinically useful marker[J]. Semin Oncol,2002,29(3):231-245.
  • 6Xu R, Perle MA, Inghirami G, et al. Amplification of HER-2/neu gene in HER-2/neu-overexpressing and-nonexpresaing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material [ J ] . Mod Pathol, 2002,15 (2) :116-124.
  • 7Selim AG, El-Ayat G, Wells CA. Expression of C-erbB-2, p53, Bcl-2,Bax,c-myc, and Ki-67 in apocrinc mctaplasia and apocrine change with in sclerosing adenosis of the breast [ J ]. Virchows Arch, 2002,441(5) : 449-455.
  • 8Latta EK,Tjan S, Parkes PK, et al. The role of HER-2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast[ J]. Mod Pathol,2002,15(12) : 1318-1325.
  • 9Xu R, Feiner H, Li P, et al. Differential amplification and overexpression of HER-2/neu. p53, MIBI, and estrogen receptor/ progesterone receptor among medullary carcinoma, a typical medullary carcinoma,and high-grade invasive duetal carcinoma of breast[J]. Arch Pathol Lab Med, 2003,127( 11 ) : 1458-1464.
  • 10郭华,魏兵,张红英,刘关键,步宏,郎志强,汤曦,戴晴晴,陈卉娇,周勇.淋巴结阴性乳腺癌患者HER2表达及其与预后相关性的Meta分析[J].中华病理学杂志,2005,34(3):140-146. 被引量：11

二级参考文献54

  • 1李树玲.新编常见恶性肿瘤诊治规范.乳腺癌分册[M].北京:北京医科大学中国协和医科大学联合出版社,1999,1.27.
  • 2Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol,1997,15:2894-2904.
  • 3Volpi A, Nanni O, De Paola F, et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol, 2003, 21:2708-2712.
  • 4Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene, 1995,159:19-27.
  • 5Schnitt SJ. Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol,2001,14: 213-218.
  • 6Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer, 1999, 85:616-628.
  • 7Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwiq) Breast Cancer Study Group. J Clin Oncol, 1992, 10:1049-1056.
  • 8Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer, 1993, 67:625-629.
  • 9Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemicaldetection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of ep idemiologic risk factors, histologic features, and prognosis. Cancer, 1995, 75:1320-1326.
  • 10Rudolph P, Olsson H, Bonatz G, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol, 1999, 187:207-216.

共引文献75

同被引文献16

  • 1吴胜其,高敏英.nm23基因蛋白表达及临床病理因素对乳腺癌预后价值的多因素Cox回归分析[J].肿瘤防治杂志,2004,11(6):597-600. 被引量：6
  • 2黄俊辉,海健,李洋,唐利立,毛杰,申郑堂,胡铁辉.原发性乳腺癌组织中c-erbB-2和nm23的表达及其意义[J].中国普通外科杂志,2004,13(11):861-863. 被引量：11
  • 3郭华,魏兵,张红英,刘关键,步宏,郎志强,汤曦,戴晴晴,陈卉娇,周勇.淋巴结阴性乳腺癌患者HER2表达及其与预后相关性的Meta分析[J].中华病理学杂志,2005,34(3):140-146. 被引量：11
  • 4Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of c - erbB- 2 expression in breast cancer[ J ]. J Surg Oncol, 2002,79 (4) :216 -231.
  • 5Linderholm B, Andersson J, Lindh B, et al. Overexpression of e - erbB - 2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node - positive breast cancer after adjuvant systemic treatment[ J]. Eur J Cancer, 2004,40( 1 ) :33 -42.
  • 6Hayes DF, Thor AD. c -erbB -2 in breast cancer: development of a clinically useful marker [ J ]. Semin Oncol, 2002,29 ( 3 ) :231 - 245.
  • 7Xu R, Perle MA, Inghirami G, et al. Amplification of HER - 2/ neu gene in HER - 2/neu - overexpressing and - nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material [ J ]. Mod Pathol, 2002,15(2) :116-124.
  • 8Selim AG, El - Ayat G, Wells CA. Expression of c - erbB - 2, p53, Bcl- 2, Bax, c- myc, and Ki- 67 in apocrine metaplasia and apocrine change with in sclerosing adenosis of the breast[J]. Virchows Arch, 2002,441 (5) :449 -455.
  • 9Latta EK, Tjan S, Parkes PK, et al. The role of HER - 2/neu overexpression/amplification in the progression of ductal carcinotua in situ to invasive carcinoma of the breast[ J]. Mod Pathol, 2002, 15(12) :1318 - 1325.
  • 10Xu R, Feiner H, Li P, et al. Differential amplification and overexpression of HER-2/neu, p53, MIBI, and estrogen receptor/progesterone receptor among medullary carcinoma, a typical medullary carcinoma, and high - grade invasive ductal carcinoma of breast [J]. Arch Pathol Lab Med, 2003,127(11) :1458 -1464.

引证文献1

二级引证文献8

医学综述
2006年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部